PKC Inhibitor

Calphostin B is a protein kinase C (PKC) inhibitor with an IC₅₀ of 1.04 μM in rats and an IC₅₀ of 22.9 μM for bovine cyclic adenosine monophosphate-dependent protein kinase (PKA). Calphostin B bears aromatic structures at positions C-14 and C-17, which accounts for its higher selectivity for PKC over PKA. Calphostin B can be used in studies related to human cervical cancer and human breast cancer.

PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC₅₀ of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature.

[Ala107]MBP(104-118) acetate is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC₅₀s ranging from 46-145 μM.

Calphostin I is a selective protein kinase C (PKC) inhibitor with an IC₅₀ of 0.14 μM in rats. Calphostin I interacts with the regulatory domain of PKC, and the aromatic groups at its C-14 and C-17 positions contribute to enhanced potency and selectivity, with no inhibition of cyclic adenosine monophosphate-dependent protein kinase (PKA) at high concentrations. Calphostin I can be used in research related to cervical cancer and breast cancer.

[Ala113]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC₅₀s ranging from 28-62 μM.

HA-100 hydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor.

[Ala107]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC₅₀s ranging from 46-145 μM.

HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor.

Calphostin D is a protein kinase C (Protein Kinase, PKC) inhibitor with an IC₅₀ of 6.4 μM. Calphostin D achieves selective inhibition by interacting with the unique C1 regulatory domain of PKC. As a photosensitizer, Calphostin D generates reactive oxygen species upon exposure to light. Calphostin D can be used in cancer-related research.

[Ala113]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC₅₀s ranging from 28-62 μM.

MS-347a is an inhibitor of myosin light chain kinase (MLCK) and protein kinase C (PKC), with IC₅₀ values of 9.2 μM, 31 μM and 16 μM against calmodulin-dependent MLCK, calmodulin-independent MLCK and PKC, respectively. MS-347a binds to the catalytic domain of MLCK and blocks both calmodulin-dependent and calmodulin-independent MLCK activity. MS-347a inhibits the growth of drug-sensitive fission yeast and multiple ascomycete phytopathogenic fungi. MS-347a exhibits fungicidal activity against a variety of phytopathogenic fungi and protective activity against Magnaporthe oryzae in rice seedlings. MS-347a shows antibacterial activity against specific Gram-positive bacteria and Proteus vulgaris. MS-347a can be used in studies related to rice blast, bacterial infections and phytopathogenic fungal diseases.

[Ala107]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC₅₀s ranging from 46-145 μM.

PRKCI Human Pre-designed siRNA Set A contains three designed siRNAs for PRKCI gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Iso-​H7 dihydrochloride is an inhibitor of protein kinase with IC₅₀ values of 22 and 34 μM to PKC and PKA respectively. Iso-H7 dihydrochloride has negative control of PKA on satellite cell myogenesis.

Valrubicin (Standard) is the analytical standard of Valrubicin. This product is intended for research and analytical applications. Valrubicin is a chemotherapy agent, inhibits TPA-and PDBu-induced PKC activation with IC₅₀s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.

NA 0345 is a PKC inhibitor with IC₅₀ values of 70 nM and 110 nM in the presence and absence of 12-O-tetradecanoyl-13-acetate, respectively. NA 0345 inhibits PKC and selectively suppresses the positive inotropic effect mediated by α₁-adrenergic receptors.

PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking.

ICA-1S is a specific PKC-ι inhibitor. ICA-1S can inhibit MAPK/JNK signaling pathway and downregulate the levels of c-Jun and TNF-α. ICA-1S inhibits the proliferation of breast cancer cells. ICA-1S induces apoptosis of breast cancer cells. ICA-1S can be used in breast cancer-related research.

ZIP TFA is a selective peptide inhibitor of PKMζ. ZIP TFA injections can block the impairment in morphine conditioned place preference induced.

Prkcq Rat Pre-designed siRNA Set A contains three designed siRNAs for Prkcq gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.